Premium
Beta‐microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma
Author(s) -
Hyakutake Hiroyuki,
Sakai Hideki,
Yogi Yasuo,
Tsuda Ryouichi,
Minami Yuzo,
Yushita Yoshiaki,
Kanetake Hiroshi,
Nakazono Ichiro,
Saito Yutaka
Publication year - 1993
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990220409
Subject(s) - prostate , immunohistochemistry , prostatic acid phosphatase , medicine , carcinoma , pathology , stage (stratigraphy) , prostate carcinoma , acid phosphatase , biopsy , anatomical pathology , cancer , biology , enzyme , paleontology , biochemistry
Abstract Human beta‐microseminoprotein (β‐MSP), isolated from seminal plasma, is one of the proteins secreted by the prostate gland. To determine whether the β‐MSP immunoreactivity can be a prognostic indicator of prostatic carcinoma, the 3‐MSP immunohistochemical distribution has been examined in needle biopsy specimens taken from 96 patients with prostatic carcinoma. Although no significant correlation was found between the β‐MSP immunoreactivity and the histological grade (Gleason score), patients with a positive β‐MSP expression had a significantly better prognosis than those with a negative 3‐MSP expression ( P = 0.01). Further, a multivariate analysis of six possible parameters (age, clinical stage, histological grade, serum prostatic acid phosphatase, β‐MSP immunoreactivity, and the type of initial treatment) has shown the difference in the β‐MSP immunoreactivity to be a significant, independent, prognostic indicator of prostatic carcinoma ( P = 0.04). © 1993 Wiley‐Liss, Inc.